Clinical Partnerships

MTIC operates within the Melbourne Biomedical Parkville precinct and, with PreMIT Pty Ltd, has University, biotech and pharmaceutical partners that will collaborate to develop and incubate new and more effective clinical solutions. This innovative translational opportunity includes the University of Melbourne Research Radiochemistry Laboratory and preclinical imaging facilities of the University of Melbourne and Monash University interdigitating with a commercial GMP-certified cyclotron facility operated by Cyclotek Australia Pty. Ltd, a Melbourne-based  SME.

Key academic partners of PreMIT include the University of Melbourne and Monash University – world-leading centres of research and learning. The respective University Departments of Medicine have unique translational capabilities.

As co-Chair of the Melbourne Academic Centre for Health (MACH) Molecular Imaging Group, Professor Hicks will support clinical trial access to state-of-the-art imaging capabilities for researchers at the St Vincent's, Royal Melbourne, Austin and Western Hospitals and the Peter MacCallum Cancer Centre, all of which are within a few few kilometres of MTIC. As a newly appointed Adjunct Professor of the Central Clinical School at the Alfred Hospital, Professor Hicks will also  facilitate access for clinical researchers at Monash University.

The University of Melbourne and Monash University will be further engaged through:

  • The Centre for Cancer Research (UMCCR), led by internationally renowned Professor Sean Grimmond.

  • Bio-21 Research Institute Chemistry led by Professor Paul Donnelly

  • Melbourne eResearch Group, led by Professor  Richard Sinnott, who has international experience in building clinical databases, complete the Parkville precinct partners

  • Monash University School of Public Health & Department of Medicine led by Prof Terry O’Brien with a focus on neuroscience

This aggregation and integration of capability is complemented by the combined research and industrial resources of;

  • Siemens Healthineers- the imaging technology giant (which has also made huge investments in artificial learning)

  • Applied Molecular Therapies (AMT), a partnership between Cyclotek and the Australian Nuclear Science and Technology Organisation (ANSTO), the national supplier of therapeutic radionuclides from its OPAL reactor, will supply GMP-certified therapeutic radiopharmaceuticals for both compassionate use and clinical trials.

  • Cyclotek, is a reliable, cost efficient and innovative supplier of Positron Emission Tomography (PET) radiopharmaceuticals. With established procedures for transitioning tracers from the research domain into production and distribution of products that meet Good Manufacturing Practice requirements of the Therapeutic Good Administration of Australia (TGA), Cyclotek represents an ideal partner for our aspiration to coordinate target to market development of novel diagnostic radiopharmaceuticals.

A series of Australian biotech, pharmaceutical and cancer industry companies have also sought to access and participate in PreMIT’s shift to its new facilitated theranostic development paradigm to rapidly translate the latest advancements in theranostic science into mainstream clinical use. These include leading entities such as:

  • Genesis Care - the largest provider of cancer care and radiation therapy in Australia

  • Clarity Pharmaceuticals - a clinical stage ASX-listed radiopharmaceutical company developing next-generation theranostic, based on SAR technology developed through collaborations with researchers at Bio-21 led by Professor Paul Donnelly and the Hicks laboratory

  • Telix Pharmaceuticals Ltd - a late-stage, ASX-listed radiopharmaceutical company head-quartered in Melbourne, which is developing a broad portfolio of diagnostic and therapeutic (‘theranostic’) radiopharmaceuticals

  • Avion Medical Skin Centres (AMSC) are the specialist treatment providers of Rhenium-SCT (skin cancer therapy) for Non-Melanoma Skin Cancers. Having worked with OncoBeta GmbH in Bringing this innovative Therapy to Australia, AMSC has now established its first treatment centre in Australia within the MTIC facility. This new treatment offers an alternative to traditional invasive options, providing most patients with improved cosmetic outcomes, in a single session, painless treatment.

Looking for an opportunity to progress your career with MTIC
MTIC Careers